SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2022
Commission File Number: 001-40212
Connect Biopharma Holdings Limited
(Translation of registrants name into English)
Science and Technology Park
East R&D Building, 3rd Floor
6 Beijing West Road, Taicang
Jiangsu Province, China 215400
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On June 10, 2022, Connect Biopharma Holdings Limited (the Company) presented certain company highlights and financial information at the 2022 Jefferies Global Healthcare Conference. A copy of the materials presented are attached hereto as Exhibit 99.1.
Among other things, the Company announced that it is midway through its Phase 2/3 pivotal trial of its lead product candidate, CBP-201, in atopic dermatitis (AD) patients in China, with the potential to receive marketing approval in China as early as 2025. The Company also completed its end-of-Phase 2 meeting with the U.S. Food and Drug Administration and is preparing to initiate a global Phase 3 trial of CBP-201 in AD in the second half of 2022. The Company is exploring potential collaborations with partners to advance this trial and, if approved, to commercialize CBP-201.
The Companys presentation also includes the following updated pipeline chart:
Figure 1. Connect Biopharmas pipeline
This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 and S-8 (Registration Nos. 333-264340 and 333-254524, respectively) of the Company and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. The information set forth in the attached exhibit shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.
The furnishing of the attached exhibit is not an admission as to the materiality of any information therein. The information contained in the exhibits is summary information that is intended to be considered in the context of more complete information included in the Companys filings with the Securities and Exchange Commission (the SEC) and other public announcements that the Company has made and may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing or furnishing of other reports or documents with the SEC, through press releases, by updating its website or through other public disclosures.
The Company cautions that statements included in this report that are not a description of historical facts are forward-looking statements. Words such as may, could, will, would, should, expect, plan, anticipate, believe, estimate, intend, predict, seek, contemplate, look forward, potential, continue or project or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Companys plans to advance the development of its product candidates, the timing of achieving any development or regulatory milestones, the potential of such product candidates, including to achieve any benefit or profile, and potential partnerships for the future development and/or commercialization of such product candidates. The inclusion of forward-looking statements shall not be regarded as a representation by Connect Biopharma that any of its plans will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Connect Biopharma business and other risks described in the Companys filings with the SEC, including the Companys Annual Report on Form 20-F filed with the SEC on March 31, 2022, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included in Connect Biopharmas filings with the SEC which are available from the SECs website (www.sec.gov) and on Connect Biopharmas website (www.connectbiopharm.com) under the heading Investors. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
|Exhibit 99.1||2022 Jefferies Global Healthcare Conference Presentation|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: June 10, 2022
CONNECT BIOPHARMA HOLDINGS LIMITED
Chief Financial Officer
Jefferies Conference Presentation – June 10, 2022 NASDAQ: CNTB DEVELOPING NEXT- GENERATION THERAPEUTICS FOR T CELL DRIVEN INFLAMMATORY DISEASES Exhibit 99.1
Forward-Looking Statements This presentation regarding Connect Biopharma Holdings Limited ("Connect," "we," "us" or "our") has been prepared solely for informational purposes. Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other data obtained from third-party sources and Connect’s own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, results of operations, business strategy and plans, prospective products and their potential benefits, potential product approvals, anticipated milestones, expected data readouts, research and development plans and costs, timing and likelihood of success, objectives of management for future operations, future results of anticipated product development efforts and adequacy of existing cash to fund operations, as well as statements regarding industry trends, are forward-looking statements. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are inherently subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among other things: the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; our ability to obtain and maintain regulatory approval of our product candidates; existing regulations and regulatory developments in the United States, the PRC, Europe and other jurisdictions; uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations; risks associated with the COVID-19 outbreak, which has and may continue to materially and adversely impact our business, preclinical studies and clinical trials; our plans and ability to obtain, maintain, protect and enforce our intellectual property rights and our proprietary technologies, including extensions of existing patent terms where available; our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; and the degree of market acceptance of our product candidates by physicians, patients, healthcare payors and others in the medical community. These risks are not exhaustive. The inclusion of forward-looking statements should not be regarded as a representation by Connect that any of its expectations, projections or plans will be achieved. Actual results may differ from those expectations, projections or plans due to the risks and uncertainties inherent in Connect’s business and other risks described in Connect’s filings with the SEC. Further information regarding these and other risks is included under the heading "Risk Factors" in Connect’s periodic reports filed with the SEC, including Connect’s Annual Report on Form 20-F filed with the SEC on March 31, 2022, and its other reports which are available from the SEC's website (www.sec.gov) and on Connect’s website (www.connectbiopharm.com) under the heading "Investors." New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
Company Highlights CBP-201: Interleukin-4-receptor alpha (IL4Rα) blocker (China Phase 2/3 Pivotal/Planning Global Phase 3) CBP-307: Sphingosine 1-phosphate-1 (S1P1) modulator CBP-174: Peripherally acting histamine-3 receptor (H3R) antagonist CBP-201: Potential first product approval for AD in China as soon as 2025*; Planning Phase 3 for AD outside of China; asthma trial opens door to additional Type II disease indications $267.7 million USD in cash and cash equivalents at December 31, 2021, expected to fund operations into at least the second half of 2023 Late-Stage Pipeline Potential Regulatory Approval Strong Cash Position Targeting inflammatory diseases (dermatology, gastroenterology, respiratory) with high unmet need representing multi-billion-dollar global market opportunities Large Opportunity Completed US FDA and China CDE discussions for CBP-201; 3 additional read outs anticipated by end of H1 2023 across 3 disease indications Multiple Catalysts Based on our understanding of standard CDE approval timeline
Recent Accomplishments and Next Anticipated Milestones CBP-201 Confirmed trial design of ongoing Phase 2/3 pivotal AD study with China CDE; topline data on track for 1H ’23; potential approval in China as soon as 2025* Completed US FDA End of Phase 2 mtg for AD, enabling partnership discussions; planning Phase 3 global program Initiated Global Phase 2 trial in asthma, laying groundwork for additional indications; topline data on track for 1H ‘23 CBP-307 Confirmed proof of mechanism and met potential registrational endpoint of Clinical Remission** in Phase 2 trial, enabling partnership discussions CBP-174 Topline data for Phase 1 trial in pruritus associated with AD on track for 2H ’22 Based on our understanding of standard CDE approval timeline **. CBP-307 2.0mg achieved Clinical Remission based on both the complete and adapted Mayo Scores, which has been accepted by the FDA as the primary endpoint in clinical trials that have supported prior approvals for treatments of UC.
Robust Pipeline of Potentially Differentiated Therapies Connect Biopharma has Global Development & Commercialization Rights to all Product Candidates INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3/Registrational NEXT ANTICIPATED MILESTONE CBP-201Antibody targeting IL-4Rα cytokine receptor (Th2 cell modulator) Atopic Dermatitis (AD) - China Trial Report pivotal study top-line in 1H’2023 Atopic Dermatitis (AD) - Global Trial Initiate Global Ph3 in 2H’2022 Asthma Report Ph2 top-line in 1H’2023 CBP-307 Small molecule targeting S1P1 (Th1 cell modulator) Ulcerative Colitis (UC) Complete maintenance phase on UC trial in 2H’2022. Seek partnerships to advance into future trials for both UC and CD. Crohn’s Disease (CD)* Seek global partnership to advance into future trials CBP-174 Peripherally restricted H3 receptor antagonist Pruritus associated with AD Report Ph1 top-line data in 2H’2022 * Phase 2 trial ended early due to COVID-19-related enrolment challenges. Future clinical development plans to be determined upon completion of Ph2 UC trial.